RT Journal Article
T1 Identification of Predictive Biomarkers of Response to HSP90 Inhibitors in Lung Adenocarcinoma
A1 Marrugal, Ángela
A1 Ferrer, Irene
A1 Gómez Sánchez, David
A1 Quintanal Villalonga, Álvaro
A1 Pastor, María Dolores
A1 Ojeda Márquez, Laura
A1 Paz-Ares Rodríguez, Luis Gonzaga
A1 Molina Pinelo, Sonia
AB Heat shock protein 90 (HSP90) plays an essential role in lung adenocarcinoma, acting as a key chaperone involved in the correct functioning of numerous highly relevant protein drivers of this disease. To this end, HSP90 inhibitors have emerged as promising therapeutic strategies, even though responses to them have been limited to date. Given the need to maximize treatment efficacy, the objective of this study was to use isobaric tags for relative and absolute quantitation (iTRAQ)-based proteomic techniques to identify proteins in human lung adenocarcinoma cell lines whose basal abundances were correlated with response to HSP90 inhibitors (geldanamycin and radicicol derivatives). From the protein profiles identified according to response, the relationship between lactate dehydrogenase B (LDHB) and DNA topoisomerase 1 (TOP1) with respect to sensitivity and resistance, respectively, to geldanamycin derivatives is noteworthy. Likewise, rhotekin (RTKN) and decaprenyl diphosphate synthase subunit 2 (PDSS2) were correlated with sensitivity and resistance to radicicol derivatives. We also identified a relationship between resistance to HSP90 inhibition and the p53 pathway by glucose deprivation. In contrast, arginine biosynthesis was correlated with sensitivity to HSP90 inhibitors. Further study of these outcomes could enable the development of strategies to improve the clinical efficacy of HSP90 inhibition in patients with lung adenocarcinoma.
PB MPDI
SN 1422-0067
YR 2021
FD 2021-03-03
LK https://hdl.handle.net/20.500.14352/7053
UL https://hdl.handle.net/20.500.14352/7053
LA eng
NO Marrugal, Á., Ferrer, I., Gómez Sánchez, D. et al. «Identification of Predictive Biomarkers of Response to HSP90 Inhibitors in Lung Adenocarcinoma». International Journal of Molecular Sciences, vol. 22, n.o 5, marzo de 2021, p. 2538. Crossref, https://doi.org/10.3390/ijms22052538.
NO Comunidad de Madrid
NO Instituto de Salud Carlos III/Fondo Europeo de Desarrollo Regional
NO Centro de Investigación Biomédica en Red de Cáncer/Fondo Europeo de Desarrollo Regional
NO Junta de Andalucía/Fondo Europeo de Desarrollo Regional
NO Asociación Española Contra el Cáncer
DS Docta Complutense
RD 8 abr 2025